US 2003/0171438 A1 · Method for treatment of external secretion disorders

Abstract

Disclosed is a method for treatment of external secretion disorders, which comprises administering a fatty acid derivative to a subject in need of said treatment. The method of the present invention is useful for treatment of at least one condition selected from hypolacrimation including disorder of basal tear secretion, dry-eye syndrome, hyposalivation and dry-mouth syndrome.

Claims15

Dependent claims

A method for treatment of external secretion disorders, which comprises administering an effective amount of a fatty acid derivative to a subject in need of said treatment.

Dependencies are inferred from the claim text.

Facts

Application

10/377,743Filed 4 Mar 2003

Priority

14 Jul 1999

Published

11 Sep 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

A61K 31/5575
Eicosanoids, e.g. leukotrienes or prostaglandins: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 9/0056
Mouth and digestive tract, i.e. intraoral and peroral administration: mouth soluble or dispersible forms; Suckable, eatable, chewable coherent…
A61K 31/20
Carboxylic acids, e.g. valproic acid: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Family

Application60/143,627Us provisional application · filed 14 Jul 1999

Application09/615,703Continuation · filed 13 Jul 2000

Application10/377,743Continuation · filed 4 Mar 2003

US 6,566,398 B1Related patent

US 2003/0171438 A1This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

10/377,743Filed 4 Mar 2003

Priority

14 Jul 1999

Published

11 Sep 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

A61K 31/5575
Eicosanoids, e.g. leukotrienes or prostaglandins: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 9/0056
Mouth and digestive tract, i.e. intraoral and peroral administration: mouth soluble or dispersible forms; Suckable, eatable, chewable coherent…
A61K 31/20
Carboxylic acids, e.g. valproic acid: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Family

Application60/143,627Us provisional application · filed 14 Jul 1999

Application09/615,703Continuation · filed 13 Jul 2000

Application10/377,743Continuation · filed 4 Mar 2003

US 6,566,398 B1Related patent

US 2003/0171438 A1This patent

From the US filing history. Foreign family members aren’t listed.

Method for treatment of external secretion disorders

Life of this patent

Abstract

Claims15

Method for treatment of external secretion disorders

Life of this patent

Abstract

Claims15